The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed ...

Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Sanofi’s Sarclisa combined with Velcade ...

NICE has recommended funding for two cancer drug combinations for ovarian cancer and multiple myeloma ... cancer that have responded to platinum chemotherapy. Early results from the phase 3 ...

For more information about how well Revlimid works to treat multiple myeloma, see the drug’s prescribing information. The National Cancer Institute has included Revlimid in its treatment ...

Sanofi’s new multiple myeloma drug Sarclisa (isatuximab ... Sanofi used to be a major player in cancer when chemotherapy was standard of care, but has not kept pace with immunotherapy ...

Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid ...

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster ...

Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the ...

Multiple Myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...

GSK's phase 3 trial shows Blenrep combined with BorDex improves overall survival in relapsed multiple myeloma.

The Orphan Drug designation was supported by preclinical research and preliminary data from the dose escalation/expansion phase 1/2 trial.

The introduction of new agents immunomodulatory drugs (IMiDs) and proteasome inhibitors ... treatment of newly diagnosed and refractory multiple myeloma (MM). Thalidomide was the first ...